Lista de obras - Zoe Moodie - Dominio Público Uruguay

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

artículo científico publicado en 2006

A New Framework for Nonparametric Estimation of the Bivariate Survivor Function ⬇️

doctoral thesis by Felicity Zoe Moodie, University of Washington, 2001

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

artículo científico publicado en 2011

An adjustment to improve the bivariate survivor function repaired NPMLE

artículo científico publicado en 2005

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

artículo científico publicado en 2020

Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus

scientific article published on 20 March 2020

Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response

artículo científico publicado en 2019

Chemoprophylaxis vaccination: Phase 1 study to explore stage-specific immunity to Plasmodium falciparum in U.S. adults

scientific article published on 17 October 2019

Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error

artículo científico publicado en 2012

Comparison of sexual behavior and HIV risk between two HIV-1 serodiscordant couple cohorts: the CHAVI 002 study

artículo científico publicado en 2012

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.

artículo científico publicado en 2015

Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals

artículo científico publicado en 2011

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

artículo científico publicado en 2013

Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy

artículo científico publicado en 2016

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

scientific article published on 13 June 2018

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection

scientific article published on 29 January 2020

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials

artículo científico publicado en 2015

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop

artículo científico publicado en 2007

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

artículo científico publicado en 2020

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

artículo científico publicado en 2008

Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial

scientific article published on 04 November 2020

Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study

artículo científico publicado en 2014

Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries

artículo científico publicado en 2020

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines ⬇️

artículo científico publicado el 1 de diciembre de 2003

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

scientific article published on 30 January 2020

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America

artículo científico publicado en 2020

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial

artículo científico publicado en 2012

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

artículo científico publicado en 2018

New clinical trial designs for HIV vaccine evaluation

artículo científico publicado en 2013

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination

artículo científico publicado en 2007

Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study

artículo científico publicado en 2014

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

artículo científico publicado en 2003

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa.

artículo científico publicado en 2009

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

article

P16-42. Characterisation of HIV-1 specific T-cell responses in exposed uninfected individuals from a London cohort

artículo científico publicado en 2009

Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease

artículo científico publicado en 2018

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

artículo científico publicado en 2006

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

artículo científico publicado en 2006

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials

artículo científico publicado en 2016

Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners

artículo científico publicado en 2013

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

artículo científico publicado en 2014

Response definition criteria for ELISPOT assays revisited

artículo científico publicado en 2010

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories

scientific article published on 01 January 2012

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

artículo científico publicado en 2011

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

artículo científico publicado en 2020

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)

artículo científico publicado en 2010

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals

artículo científico publicado en 2006

Self-reported Benefits of Study Participation in HVTN 503, “Phambili”.

artículo científico publicado en 2014

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

artículo científico publicado en 2021

Statistical evaluation of HIV vaccines in early clinical trials.

artículo científico publicado en 2006

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials

artículo científico publicado en 2006

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

artículo científico publicado en 2018

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083

artículo científico publicado en 2015

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells

scientific article published on 27 November 2019

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype

artículo científico publicado en 2010

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

artículo científico publicado en 2021

Lista de obras de Zoe Moodie

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

A New Framework for Nonparametric Estimation of the Bivariate Survivor Function ⬇️

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

An adjustment to improve the bivariate survivor function repaired NPMLE

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus

Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response

Chemoprophylaxis vaccination: Phase 1 study to explore stage-specific immunity to Plasmodium falciparum in U.S. adults

Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error

Comparison of sexual behavior and HIV risk between two HIV-1 serodiscordant couple cohorts: the CHAVI 002 study

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.

Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial

Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study

Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines ⬇️

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

New clinical trial designs for HIV vaccine evaluation

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination

Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa.

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

P16-42. Characterisation of HIV-1 specific T-cell responses in exposed uninfected individuals from a London cohort

Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials

Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Response definition criteria for ELISPOT assays revisited

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals

Self-reported Benefits of Study Participation in HVTN 503, “Phambili”.

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

Statistical evaluation of HIV vaccines in early clinical trials.

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection